Insurance Dropped Your GLP-1? 5 Cheapest Options (2026)
41 million Americans lost commercial GLP-1 coverage in 2026. CVS Caremark dropped Zepbound, BCBS restricted Wegovy. Here are the cheapest ways to keep your medication without insurance.
If your insurance recently dropped GLP-1 coverage, you have more options than the news headlines suggest. The cash-pay landscape in 2026 is different from 2024 — there are five reasonable paths to keep continuity.
Key takeaways
- Compounded GLP-1 telehealth programs start at $99/month
- Direct manufacturer self-pay programs for brand-name drugs are now $349/month for Wegovy and $499 for Zepbound
- Oral options like Foundayo or Rybelsus avoid the cold-chain shipping concerns of injections
- Generic Saxenda (liraglutide) is materially cheaper but requires daily injection
- Switching providers should be coordinated with your current prescriber to avoid a treatment gap
Option 1 — Compounded telehealth
By a wide margin, this is the most common path for displaced patients. Compounded semaglutide and tirzepatide deliver the same active ingredients as brand-name drugs, prepared in 503A licensed pharmacies under provider supervision.
The economics are structurally different — no manufacturer markup, no insurance friction, and longer-plan pricing rewards commitment.
Option 2 — Direct manufacturer self-pay
Both Novo Nordisk and Eli Lilly have introduced direct cash-pay programs in response to coverage cuts. Wegovy is around $349/month and Zepbound around $499/month. These are FDA-approved and the cleanest regulatory path, but more than triple the cost of compounded.
Options 3–5 — Oral, generic, and bridge plans
Foundayo and oral Wegovy provide pill-format alternatives for patients who can't or won't inject. Generic liraglutide (Saxenda) has been around longest and is materially cheaper but requires daily injection. Several telehealth programs also offer bridge plans designed to maintain continuity for 1–3 months while patients evaluate next steps.